In glioma cells, a specific point mutation occurs relatively often at the Arg132 location of the IDH1 protein (NADP+-dependent isocitrate dehydrogenase 1) resulting in a gain-of-function mutation that produces D-2-hydroxyglutarate (D-2HG), a prevalent metabolite attributed to carcinogenesis and tumor progression.1 The TB096-2 cell line provides a strong in vitro model to further understand the role of IDH1 mutation in astrocytoma growth mediated by D-2HG conversion. This also provides opportunity to develop therapy solutions which may modulate D-2HG production and help understand the role of wild type IDH1 in conjunction with its mutated allele.，官网链接：https://www.sigmaaldrich.cn/product/mm/scc431 默克 科研、开发、生产。 作为生命科学行业的全球领先供应商，我们致力于为科研、生物技术开发和生产，以及制药药物疗法开发和生产提供各类解决方案和服务。

非质量问题不退不换